Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19: a meta-analysis

W Wen, C Chen, J Tang, C Wang, M Zhou… - Annals of …, 2022 - Taylor & Francis
Background The coronavirus disease (COVID-19) epidemic has not been completely
controlled. Although great achievements have been made in COVID-19 research and many …

Molnupiravir and its antiviral activity against COVID-19

L Tian, Z Pang, M Li, F Lou, X An, S Zhu… - Frontiers in …, 2022 - frontiersin.org
The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) constitutes a major worldwide public health threat …

Novel investigational anti-SARS-CoV-2 agent ensitrelvir “S-217622”: a very promising potential universal broad-spectrum antiviral at the therapeutic frontline of …

WA Eltayb, M Abdalla, AM Rabie - ACS omega, 2023 - ACS Publications
Lately, nitrogenous heterocyclic antivirals, such as nucleoside-like compounds, oxadiazoles,
thiadiazoles, triazoles, quinolines, and isoquinolines, topped the therapeutic scene as …

Oral antiviral treatments for COVID-19: opportunities and challenges

L Rahmah, SO Abarikwu, AG Arero, M Essouma… - Pharmacological …, 2022 - Springer
The use of antiviral COVID-19 medications can successfully inhibit SARS-CoV-2 replication
and prevent disease progression to a more severe form. However, the timing of antiviral …

Molnupiravir: A lethal mutagenic drug against rapidly mutating severe acute respiratory syndrome coronavirus 2—A narrative review

S Masyeni, M Iqhrammullah… - Journal of Medical …, 2022 - Wiley Online Library
Broad‐spectrum antiviral agents targeting viral RNA‐dependent RNA polymerase (RdRp)
are expected to be a key therapeutic strategy in the ongoing coronavirus disease 2019 …

Effectiveness of molnupiravir in high-risk patients: a propensity score matched analysis

R Najjar-Debbiny, N Gronich, G Weber… - Clinical infectious …, 2023 - academic.oup.com
Background Molnupiravir was granted emergency use authorization for the treatment of mild
to moderate coronavirus disease 2019 (COVID-19). In this study, we used population-based …

Highly sensitive high‐performance thin‐layer chromatography method for the simultaneous determination of molnupiravir, favipiravir, and ritonavir in pure forms and …

RE Saraya, SE Deeb, BI Salman… - Journal of separation …, 2022 - Wiley Online Library
Favipiravir, molnupiravir, and ritonavir have been recently approved as the first oral
antivirals for treatment of SARS‐CoV‐2 viral infections. Their combination was reported in …

Pharmacological treatment of COVID-19: an opinion paper

A García-Lledó, J Gómez-Pavón… - Revista Española …, 2021 - pmc.ncbi.nlm.nih.gov
The precocity and efficacy of the vaccines developed so far against COVID-19 has been the
most significant and saving advance against the pandemic. The development of vaccines …

The therapeutic and prophylactic potential of quercetin against COVID-19: An outlook on the clinical studies, inventive compositions, and patent literature

M Imran, HK Thabet, SI Alaqel, AR Alzahrani, A Abida… - Antioxidants, 2022 - mdpi.com
Quercetin is a phenolic flavonol compound with established antioxidant, anti-inflammatory,
and immuno-stimulant properties. Recent studies demonstrate the potential of quercetin …

Key considerations during the transition from the acute phase of the COVID-19 pandemic: a narrative review

P Rzymski, M Pokorska-Śpiewak, T Jackowska… - Vaccines, 2023 - mdpi.com
The COVID-19 pandemic has been met with an unprecedented response from the scientific
community, leading to the development, investigation, and authorization of vaccines and …